PDF(Pubmed)
Abstract：
UNASSIGNED: The present study aimed to evaluate the clinical value of Combined Detection of serum soluble T-cell immunoglobulin 3 (sTim-3) with carcinoembryonic antigen (CEA) or glycotype antigen 19-9 (CA19-9) for Postoperative Recurrence of Colorectal Cancer (CRC) Diagnosis.
UNASSIGNED: The serum sTim-3 was measured by highly sensitivity TRFIA, and serum CEA and CA19-9 were obtained through the collection of clinical data. Quantitative detection of serum sTim-3, CEA, CA19-9 in 90 patients after the CRC surgery (52 postoperative recurrence and 38 no-postoperative recurrence), 21 patients with colorectal benign tumors, and 67 healthy controls. To analyze the clinical diagnostic value of combined detection of sTim-3 with CEA or CA19-9 to test whether patients have recurrence after CRC surgery.
UNASSIGNED: The sTim-3 (15.94±11.24ng/mL) in patients after CRC surgery was significantly higher than in healthy controls (8.95±3.34ng/mL) and colorectal benign tumors (8.39±2.28ng/mL) (P < 0.05), and sTim-3 (20.33±13.04ng/mL) in CRC postoperative recurrent group was significantly higher than in the group without recurrence after CRC surgery (9.94±2.36ng/mL) (P < 0.05). In terms of detecting postoperative recurrence after CRC surgery, combined detection of sTim-3 and CEA (AUC: 0.819, sensitivity: 80.77%, specificity: 65.79%), sTim-3 and CA19-9 test (AUC: 0.813, sensitivity: 69.23%, specificity: 97.30%) was significantly better than the CEA single test (AUC: 0.547, sensitivity: 63.16%, specificity: 48.08%) and CA19-9 single test (AUC: 0.675 sensitivity: 65.38%, specificity: 67.57%), Delong test P < 0.05.
UNASSIGNED: The efficacy of CEA and CA19-9 single test was not optimal, and the combination of sTim-3 in serum could significantly improve the sensitivity and specificity of detecting patient recurrence after CRC surgery.
UNASSIGNED: The serum sTim-3 was measured by highly sensitivity TRFIA, and serum CEA and CA19-9 were obtained through the collection of clinical data. Quantitative detection of serum sTim-3, CEA, CA19-9 in 90 patients after the CRC surgery (52 postoperative recurrence and 38 no-postoperative recurrence), 21 patients with colorectal benign tumors, and 67 healthy controls. To analyze the clinical diagnostic value of combined detection of sTim-3 with CEA or CA19-9 to test whether patients have recurrence after CRC surgery.
UNASSIGNED: The sTim-3 (15.94±11.24ng/mL) in patients after CRC surgery was significantly higher than in healthy controls (8.95±3.34ng/mL) and colorectal benign tumors (8.39±2.28ng/mL) (P < 0.05), and sTim-3 (20.33±13.04ng/mL) in CRC postoperative recurrent group was significantly higher than in the group without recurrence after CRC surgery (9.94±2.36ng/mL) (P < 0.05). In terms of detecting postoperative recurrence after CRC surgery, combined detection of sTim-3 and CEA (AUC: 0.819, sensitivity: 80.77%, specificity: 65.79%), sTim-3 and CA19-9 test (AUC: 0.813, sensitivity: 69.23%, specificity: 97.30%) was significantly better than the CEA single test (AUC: 0.547, sensitivity: 63.16%, specificity: 48.08%) and CA19-9 single test (AUC: 0.675 sensitivity: 65.38%, specificity: 67.57%), Delong test P < 0.05.
UNASSIGNED: The efficacy of CEA and CA19-9 single test was not optimal, and the combination of sTim-3 in serum could significantly improve the sensitivity and specificity of detecting patient recurrence after CRC surgery.
摘要：
■本研究旨在评估血清可溶性T细胞免疫球蛋白3（sTim-3）与癌胚抗原（CEA）或糖型抗原19-9（CA19-9）联合检测在结直肠癌（CRC）术后复发诊断中的临床价值。
■通过高灵敏度TRFIA测量血清sTim-3，通过收集临床资料获得血清CEA和CA19-9。定量检测血清sTim-3、CEA、90例CRC术后患者CA19-9（52例术后复发，38例无术后复发），21例结直肠良性肿瘤，和67个健康对照。分析sTim-3联合CEA或CA19-9检测对CRC术后患者是否复发的临床诊断价值。
■CRC术后患者sTim-3(15.94±11.24ng/mL)明显高于健康对照组(8.95±3.34ng/mL)和结直肠良性肿瘤(8.39±2.28ng/mL)(P<0.05),CRC术后复发组sTim-3(20.33±13.04ng/mL)明显高于CRC术后无复发组(9.94±2.36ng/mL)(P<0.05)。在检测CRC术后复发方面，联合检测sTim-3和CEA（AUC：0.819，灵敏度：80.77%，特异性：65.79%），sTim-3和CA19-9测试（AUC：0.813，灵敏度：69.23％，特异性：97.30%）明显优于CEA单一检测（AUC：0.547，灵敏度：63.16%，特异性：48.08%）和CA19-9单一测试（AUC：0.675灵敏度：65.38%，特异性：67.57%），Delong检验P<0.05。
■CEA和CA19-9单一试验的疗效并不理想，血清中sTim-3的联合检测可显著提高CRC术后患者复发的敏感性和特异性。
■通过高灵敏度TRFIA测量血清sTim-3，通过收集临床资料获得血清CEA和CA19-9。定量检测血清sTim-3、CEA、90例CRC术后患者CA19-9（52例术后复发，38例无术后复发），21例结直肠良性肿瘤，和67个健康对照。分析sTim-3联合CEA或CA19-9检测对CRC术后患者是否复发的临床诊断价值。
■CRC术后患者sTim-3(15.94±11.24ng/mL)明显高于健康对照组(8.95±3.34ng/mL)和结直肠良性肿瘤(8.39±2.28ng/mL)(P<0.05),CRC术后复发组sTim-3(20.33±13.04ng/mL)明显高于CRC术后无复发组(9.94±2.36ng/mL)(P<0.05)。在检测CRC术后复发方面，联合检测sTim-3和CEA（AUC：0.819，灵敏度：80.77%，特异性：65.79%），sTim-3和CA19-9测试（AUC：0.813，灵敏度：69.23％，特异性：97.30%）明显优于CEA单一检测（AUC：0.547，灵敏度：63.16%，特异性：48.08%）和CA19-9单一测试（AUC：0.675灵敏度：65.38%，特异性：67.57%），Delong检验P<0.05。
■CEA和CA19-9单一试验的疗效并不理想，血清中sTim-3的联合检测可显著提高CRC术后患者复发的敏感性和特异性。
